Intellia Therapeutics Inc (NASDAQ:NTLA) has received a consensus recommendation of “Hold” from the twelve ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $30.40.
Several analysts recently weighed in on the company. Barclays reissued a “buy” rating on shares of Intellia Therapeutics in a report on Sunday, November 5th. TheStreet lowered Intellia Therapeutics from a “c-” rating to a “d” rating in a report on Thursday, December 14th. BidaskClub lowered Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 15th. ValuEngine lowered Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Finally, Oppenheimer reissued a “hold” rating on shares of Intellia Therapeutics in a report on Monday, December 18th.
Shares of Intellia Therapeutics (NASDAQ NTLA) opened at $22.95 on Tuesday. The firm has a market capitalization of $848.92, a PE ratio of -14.71 and a beta of 3.60. Intellia Therapeutics has a fifty-two week low of $10.83 and a fifty-two week high of $33.34.
A number of hedge funds have recently modified their holdings of NTLA. Schwab Charles Investment Management Inc. boosted its stake in Intellia Therapeutics by 58.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 42,674 shares of the company’s stock valued at $683,000 after acquiring an additional 15,771 shares during the period. Rhumbline Advisers acquired a new position in shares of Intellia Therapeutics during the second quarter worth approximately $275,000. Bank of New York Mellon Corp boosted its position in shares of Intellia Therapeutics by 73.0% during the second quarter. Bank of New York Mellon Corp now owns 54,802 shares of the company’s stock worth $876,000 after buying an additional 23,126 shares during the period. Wells Fargo & Company MN boosted its position in shares of Intellia Therapeutics by 176.1% during the second quarter. Wells Fargo & Company MN now owns 30,215 shares of the company’s stock worth $483,000 after buying an additional 19,270 shares during the period. Finally, Alliancebernstein L.P. boosted its position in shares of Intellia Therapeutics by 17.8% during the second quarter. Alliancebernstein L.P. now owns 30,400 shares of the company’s stock worth $486,000 after buying an additional 4,600 shares during the period. Institutional investors own 48.12% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.